Zygomycosis
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Synonyms and keywords: Zygomycosis
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Zygomycosis is a rare yet life threatening and serious infection of fungi, usually affecting the face or oropharyngeal cavity. Occasionally, when caused by Pythium or other similar fungi, the condition may affect the gastrointestinal tract or the skin. It usually begins in the nose and paranasal sinuses and is one of the most rapidly spreading fungal infections in humans.[1] The most common fungi responsible for mucormycosis in humans are Mucor and Rhizopus. Other fungi include Apophysomyces, Absidia, Mortierella, Cunninghamella, Saksenaea, Syncephalastrum and Cokeromyces, although the spectrum is far wider and can also contain Entomophthorales or Mucorales.[2] It usually affects patients who are immunocompromised.[1]
Basidiobolomycosis is a rare disease caused by the fungus Basidiobolus ranarum, member of the class Zygomycetes, order Entomophthorales, found worldwide. Usually basidiobolomycosis is a subcutaneous infection but it has been associated with gastrointestinal disease.
Pathophysiology
The clinical hallmark of Zygomycosis is vascular invasion resulting in thrombosis and tissue infarction/necrosis.
Causes
Zygomycosis caused by Mucorales causes a rapidly progressing disease of sudden onset in sick or immunocompromised animals. Entomophthorales cause chronic, local infections in otherwise healthy animals. The important species that cause entomophthoromycosis are Conidiobolus coronatus, C. incongruous, and Basidiobolus ranarum. Conidiobolus infections of the upper respiratory system have been reported in humans, sheep, horses, and dogs, and Basidiobolus has been reported less commonly in humans and dogs.[3] Horses are one of the most common domestic animals to be affected by entomophthoromycosis. C. coronatus causes lesions in the nasal and oral mucosa of horses that may cause nasal discharge or difficulty breathing. B. ranarum causes large circular nodules on the upper body and neck of horses. Entomophthorales is found in soil and decaying plant matter, and specifically Basidiobolus can be contracted from insects and the feces of reptiles or amphibians. Zygomycosis of the sinuses can extend from the sinuses into the orbit and the cranial vault, leading to rhinocerebral mucormycosis.
Differentiating Zygomycosis from other Diseases
Zygomycosis needs to be differentiated from conditions like anthrax, aspergillosis and cellulitis.
Epidemiology and Demographics
Zygomycosis is a very rare infection, and as such it is hard to note histories of patients and incidence of the infection. However, one American oncology center revealed that zygomycosis was found in 0.7% of autopsies and roughly 20 patients per every 100,000 admissions to that center. In the United States, zygomycosis was most commonly found in the form of Rhinocerebral disease. In most cases the patient is immunocompromised, although rare cases have occurred in which the subject was not immunocompromised, most often due to a traumatic inoculation of fungal spores. Internationally, zygomycosis was found in 1% of patients with acute leukemia in an Italian review.
Risk Factors
While most individuals are exposed to the fungi on a regular basis those with immune disorders are more prone to an infection.[4] In humans zygomycosis is most prevalent in immunocompromised patients (HIV/AIDS, the elderly, SCID, etc) and patients in acidosis (diabetes, burns), particularly after barrier injury to the skin or mucus membranes, malignancies such as lymphomas and leukemias, renal failure, organ transplant, long term corticosteroid and immunosuppressive therapy, cirrhosis, burns and energy malnutrition. Some 50-75% of patients diagnosed with zygomycosis are estimated to have underlying poorly controlled diabetes mellitus and ketoacidosis.
Natural History, Complications and Prognosis
In most cases, the prognosis of zygomycosis is poor and has varied mortality rates depending on its form and severity. In the Rhinocerebral form, the mortality rate is between 30% and 70%, whereas disseminated zygomycosis presents with the highest mortality rate in an otherwise healthy patient with a mortality rate of up to 90%. Patients with AIDS have a mortality rate of almost 100%. Possible complications of Zygomycosis include the partial loss of neurological function, blindness and clotting of brain or lung vessels.
Diagnosis
Laboratory Findings
Diagnosis for phycomycosis is through a biopsy or culture, although an ELISA test has been developed for Pythium insidiosum in animals.[5] As swabs of tissue or discharge are generally unreliable, the diagnosis of zygomycosis tends to be established by a biopsy specimen of the involved tissue. Diagnosis for basidiobolomycosis is by laboratory culture of the organism, usually from pieces of tissue taken from the patient. It grows easily on most media, but risks being discarded as irrelevant or being reported as a contaminant because laboratory staff are unfamiliar with it. Diagnosis is often difficult because basidiobolomycosis is a rare disease and therefore often not recognized. The lesions often look like tumors rather than infection, so often no sample is sent for microbiology, however, the histopathology is characteristic: the Splendore-Hoeppli phenomenon describes the presence of fungal hyphae (which may exist only as ghosts on the slide) surrounded by eosinophilic material.
In patients with deep involvement with Basidiobolomycosis, the eosinophil count may be raised, falsely suggesting a parasitic infection.
Treatment
Medical Therapy
If zygomycosis is suspected, prompt amphotericin B therapy should be administered due to the rapid spread and mortality rate of the disease. Amphotericin B (which works by damaging the cell walls of the fungi) is usually administered for a further 4-6 weeks after initial therapy begins to ensure eradication of the infection. Posaconazole has been shown to be effective against zygomycosis, perhaps more so than amphotericin B, but has not yet replaced it as the standard of care. After administration the patient must then be admitted to surgery for removal of the “fungus ball“. The disease must be monitored carefully for any signs of reemergence. Treatment for skin lesions is traditionally with potassium iodide,[6] but itraconazole has also been used successfully.[7][8] Antifungal drugs show only limited effect on treatment of phycomycosis, but itraconazole and terbinafine hydrochloride are often used for two to three months following surgery. Humans with Basidiobolus infections have been treated with amphotericin B and potassium iodide. Immunotherapy has been used successfully in humans and horses with pythiosis.
Surgery
Surgical therapy can be very drastic for zygomycosis, and in some cases of Rhinocerebral disease removal of infected brain tissue may be required. In some cases surgery may be disfiguring because it may involve removal of the palate, nasal cavity, or eye structures. Surgery may be extended to more than one operation. It has been hypothesised that hyperbaric oxygen may be beneficial as an adjunctive therapy because higher oxygen pressure increases the ability of neutrophils to kill the organism.
Treatment for Phycomycosis is very difficult and includes surgery when possible. Postoperative recurrence is common. For pythiosis and lagenidiosis, a new drug targeting water moulds called caspofungin is available, but it is very expensive. For pythiosis and lagenidiosis, a new drug targeting water moulds called caspofungin is available, but it is very expensive.
Primary Prevention
Because the fungi that cause zygomycosis are widespread, the most appropriate preventive measures involve improved control of the underlying illnesses associated with zygomycosis.
References
- ↑ 1.0 1.1 Auluck A (2007). “Maxillary necrosis by mucormycosis. a case report and literature review” (PDF). Med Oral Patol Oral Cir Bucal. 12 (5): E360–4. PMID 17767099. Retrieved 2008-04-20.
- ↑ Ettinger, Stephen J.;Feldman, Edward C. (1995). Textbook of Veterinary Internal Medicine (4th ed. ed.). W.B. Saunders Company. ISBN 0-7216-6795-3.
- ↑ Greene C, Brockus C, Currin M, Jones C (2002). “Infection with Basidiobolus ranarum in two dogs”. J Am Vet Med Assoc. 221 (4): 528–32, 500. PMID 12184703.
- ↑ “MedlinePlus Medical Encyclopedia: Mucormycosis”. Retrieved 2008-04-21.
- ↑ Hensel P, Greene C, Medleau L, Latimer K, Mendoza L (2003). “Immunotherapy for treatment of multicentric cutaneous pythiosis in a dog”. J Am Vet Med Assoc. 223 (2): 215–8, 197. PMID 12875449.
- ↑ Nazir Z, Hasan R, Pervaiz S, Alam M, Moazam F. (1997). “Invasive retroperitoneal infection due to Basidiobolus ranarum with response to potassium iodide—case report and review of the literature”. Ann Trop Paediatr. 17 (2): 161&ndash, 4. PMID 9230980.
- ↑ Yusuf NW, Assaf HM, Rotowa N (2003). “Invasive gastrointestinal Basidiobolus ranarum infection in an immunocompetent child (brief report)”. Ped Infect Dis J. 22 (3): 281&ndash, 82.
- ↑ Mathew RM, Kumaravel S, Kuruvilla S; et al. (2005). “Successful treatment of extensive basidiobolomycosis with oral itraconazole in a child”. Int J Dermatol. 44 (7): 572&ndash, 75.
Historical Perspective
Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.
References
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.
Overview
The clinical hallmark of Zygomycosis is vascular invasion resulting in thrombosis and tissue infarction/necrosis.
References
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.
Overview
Zygomycosis usually is a disease of the skin, but can also occur in the sinuses or gastrointestinal tract. Zygomycosis caused by Mucorales causes a rapidly progressing disease of sudden onset in sick or immunocompromised animals. Entomophthorales cause chronic, local infections in otherwise healthy animals. The important species that cause entomophthoromycosis are Conidiobolus coronatus, C. incongruous, and Basidiobolus ranarum. Conidiobolus infections of the upper respiratory system have been reported in humans, sheep, horses, and dogs, and Basidiobolus has been reported less commonly in humans and dogs.[1] Horses are one of the most common domestic animals to be affected by entomophthoromycosis. C. coronatus causes lesions in the nasal and oral mucosa of horses that may cause nasal discharge or difficulty breathing. B. ranarum causes large circular nodules on the upper body and neck of horses. Entomophthorales is found in soil and decaying plant matter, and specifically Basidiobolus can be contracted from insects and the feces of reptiles or amphibians. Zygomycosis of the sinuses can extend from the sinuses into the orbit and the cranial vault, leading to rhinocerebral mucormycosis.
References
- ↑ Greene C, Brockus C, Currin M, Jones C (2002). “Infection with Basidiobolus ranarum in two dogs”. J Am Vet Med Assoc. 221 (4): 528–32, 500. PMID 12184703.
Differentiating Zygomycosis from other Diseases
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.
Overview
Zygomycosis needs to be differentiated from conditions like anthrax, aspergillosis and cellulitis.
References
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Zygomycosis is a very rare infection, and as such it is hard to note histories of patients and incidence of the infection. However, one American oncology center revealed that zygomycosis was found in 0.7% of autopsies and roughly 20 patients per every 100,000 admissions to that center. In the United States, zygomycosis was most commonly found in the form of Rhinocerebral disease. In most cases the patient is immunocompromised, although rare cases have occurred in which the subject was not immunocompromised, most often due to a traumatic inoculation of fungal spores. Internationally, zygomycosis was found in 1% of patients with acute leukemia in an Italian review.
Outbreaks
Outbreaks and clusters of mucormycosis are rare but when they do occur they are often serious. In hospitals, mucormycosis outbreaks of skin and soft tissue infection have been linked to contact with contaminated objects, such as tongue depressors. Additionally, clusters of mucormycosis have occurred in association with organ transplantation. The most recent investigation was in response to an outbreak of mucormycosis among victims of the Joplin, Missouri tornado in May 2011.
Information about Mucormycosis following the Joplin, Missouri Tornado
CDC is assisting the Missouri Department of Health and Senior Services (MDHSS) with an investigation into a number of reports of fungal skin infection in people who were injured by the tornado that struck Joplin in May 2011. People who had trauma that resulted in an open wound that is not healing or are experiencing continued symptoms, such as worsening redness, tenderness, pain, heat in the area of the wound, or fever, should see a health care provider for evaluation.[1]
References
- ↑ “CDC – Diagnosis & Testing of Mucormycosis – Mucormycosis”. Retrieved 22 November 2013.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It’s easy! Click here to learn about editing.
Overview
While most individuals are exposed to the fungi on a regular basis those with immune disorders are more prone to an infection.[1] In humans zygomycosis is most prevalent in immunocompromised patients (HIV/AIDS, the elderly, SCID, etc) and patients in acidosis (diabetes, burns), particularly after barrier injury to the skin or mucus membranes, malignancies such as lymphomas and leukemias, renal failure, organ transplant, long term corticosteroid and immunosuppressive therapy, cirrhosis, burns and energy malnutrition. Some 50-75% of patients diagnosed with zygomycosis are estimated to have underlying poorly controlled diabetes mellitus and ketoacidosis.
Risk factors
Mucormycosis is a rare infection caused by fungi typically found in the soil and in decaying organic matter, including leaves and rotten wood. The infection is more common among people with weakened immune systems, but it can occur (rarely) in people who are otherwise healthy. Risk factors for developing mucormycosis include:
- Uncontrolled diabetes
- Cancer
- Organ transplant
- Neutropenia (low white blood cells)
- Skin trauma (cuts, scrapes, punctures, or burns)[2]
References
- ↑ “MedlinePlus Medical Encyclopedia: Mucormycosis”. Retrieved 2008-04-21.
- ↑ “CDC – People at Risk For Mucormycosis – Mucormycosis”. Retrieved 22 November 2013.
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
In most cases, the prognosis of zygomycosis is poor and has varied mortality rates depending on its form and severity. In the Rhinocerebral form, the mortality rate is between 30% and 70%, whereas disseminated mucormycosis presents with the highest mortality rate in an otherwise healthy patient with a mortality rate of up to 100%. Patients with AIDS have a mortality rate of almost 100%. Possible complications of mucormycosis include the partial loss of neurological function, blindness and clotting of brain or lung vessels.
Natural History[1]
If left untreated, mucormycosis can be fatal. The survival rate of immunosuppressed patients with rhino sinusal mucormycosis without cerebral involvement is between 50-80% and only 10% if the infection spreads into the brain. In uncontrolled diabetes mellitus patients with ketoacidosis that are diagnosed with rhino-orbital mucormycosis we should suspect a cerebral spread of the fungi if after 24 hours since the beginning of treatment. In 70% of cases mucormycosis occurs in diabetics, and the percentage increases if there is concomitant immunosupression and comorbities.
Complications[2]
- Patients with mucormycosis may develop the following complications:
- Extensive necrosis
- Fungemia leading to septic shock
- Stroke
- Paralysis
- Ophtalmoplegia
- Intra-cranial hemorrhage
- Mediastinitis
- Bronchial perforation
- Pulmonary gangrene
- Renal mucormycosis
Prognosis[3]
- The overall survival rate of patients with mucormycosis is approximately 50%, although survival rates approaching up to 85% have been reported.
- Differences in prognosis are due to the various forms of the disease.
- Rhinocerebral mucormycosis has a higher survival rate than does pulmonary or disseminated mucormycosis because the rhinocerebral disease can frequently be diagnosed earlier and the most common underlying cause, diabetic ketoacidosis, can be treated readily.
- Pulmonary mucormycosis has a high mortality (around 65 percent at 1 year)[4]
- Mortality in patients with disseminated disease approaches 100%, majorly due to surgical removal of infected tissues is not feasible and in part because these patients are usually most highly immunocompromised.[5]
References
- ↑ Nicolae M, Popescu CR, Popescu B, Grigore R (2013). “Orbital complications of fungal pan-sinusitis in uncontrolled diabetes”. Maedica (Buchar). 8 (3): 276–9. PMC 3869119. PMID 24371499.
- ↑ Dhooria S, Agarwal R, Chakrabarti A (2015). “Mediastinitis and Bronchial Perforations Due to Mucormycosis”. J Bronchology Interv Pulmonol. 22 (4): 338–42. doi:10.1097/LBR.0000000000000170. PMID 26348693.
- ↑ Parfrey NA (1986). “Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases”. Medicine (Baltimore). 65 (2): 113–23. PMID 3951358.
- ↑ Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002). “Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients”. Clin. Infect. Dis. 34 (7): 909–17. doi:10.1086/339202. PMID 11880955.
- ↑ Spellberg B, Edwards J, Ibrahim A (2005). “Novel perspectives on mucormycosis: pathophysiology, presentation, and management”. Clin. Microbiol. Rev. 18 (3): 556–69. doi:10.1128/CMR.18.3.556-569.2005. PMC 1195964. PMID 16020690.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | X Ray | CT | MRI | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
